Kidney Diseases最新文献

{"title":"Erratum.","authors":"","doi":"10.1159/000546078","DOIUrl":"https://doi.org/10.1159/000546078","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000520586.].</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"319"},"PeriodicalIF":3.2,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Relationship between Renal Interstitial Vasculopathy and Clinical and Prognosis of Patients with Lupus Nephritis.","authors":"Xiuhua Ma, Xudong Liu, Xuan Wang, Min Yu, Xiaoling Zhou","doi":"10.1159/000545989","DOIUrl":"10.1159/000545989","url":null,"abstract":"<p><strong>Introduction: </strong>Renal vascular lesions (RVLs) are a common histopathological feature in lupus nephritis (LN). Despite their frequent occurrence, the clinical significance and prognostic impact of RVLs remain poorly understood. The main objectives of our study were to investigate the clinicopathological characteristics associated with RVLs in LN and to assess their prognostic implications in patients with LN.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of baseline clinical and pathological data, as well as outcomes, for patients diagnosed with biopsy-confirmed lupus nephritis between September 1, 2008, and October 31, 2021. Patients were initially stratified into two groups based on the presence or absence of vascular disease at baseline. Subsequently, they were further categorized into four groups according to the severity of vascular disease. Comparisons were made across these groups with respect to clinical and laboratory parameters, pathological features, and prognostic outcomes. The composite endpoint was defined as death, end-stage renal disease (ESRD), or a ≥30% increase in serum creatinine. Survival analysis was performed using the Kaplan-Meier method to compare the renal survival and overall survival between groups with different severities of RVLs. The log-rank test was employed for univariate survival analysis, and multivariate analysis of survival outcomes was performed using the Cox regression model.</p><p><strong>Results: </strong>In a group of 225 patients, RVLs were found in 101 kidney biopsies, with 72 of these being mild. Among 156 patients with proliferative lupus nephritis, 77 had RVLs. Patients with RVLs were older and exhibited higher levels of serum creatinine, blood urea, uric acid, C-reactive protein, and significantly higher chronicity index and SLEDAI scores. They also had more severe tubulointerstitial lesions, worse clinical manifestations, and lower complete remission rates. Their estimated glomerular filtration rate was lower (<i>p</i> < 0.05). Compared to the NRVLs group, patients in the RVLs group had a lower renal survival rate and overall survival rate, and a significant difference was observed between the groups (<i>p</i> < 0.05). Importantly, the severity of vascular lesions was associated with a lower renal survival rate and overall survival rate, especially in proliferative lupus nephritis.</p><p><strong>Conclusion: </strong>RVLs are a common pathological feature in lupus nephritis and are particularly prevalent among patients with proliferative lupus nephritis. The presence and severity of RVLs are associated with more severe clinicopathological manifestations and a lower complete remission rate in lupus nephritis patients. Furthermore, they are predictive of poorer long-term outcomes, with a particularly pronounced impact on those with proliferative lupus nephritis.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"377-389"},"PeriodicalIF":3.2,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12162118/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144285061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interferon-Stimulated Genes: Novel Targets in Renal Pathogenesis.","authors":"Meng Jia, Shuangxu Han, Liang Li, Yi Fu, Di Zhou","doi":"10.1159/000546141","DOIUrl":"10.1159/000546141","url":null,"abstract":"<p><strong>Background: </strong>Kidney diseases are a prevalent global health concern, and despite ongoing research, there remains a lack of fully effective clinical treatments to prevent or halt their progression. Consequently, it is encouraged to identify novel biomarkers, establish early diagnostic methods, pinpoint key molecular pathways, and develop innovative therapeutic targets for more effective management of renal disorders.</p><p><strong>Summary: </strong>Interferons (IFNs), a group of cytokines, play pivotal roles in immune responses, particularly in antiviral and antiproliferative activities. IFNs trigger a cascade of signaling events that lead to the induction of interferon-stimulated genes (ISGs), which are essential for controlling viral infections and regulating immune responses. This review explores the impact of interferon-related genes on renal disorders, focusing on the mechanisms, therapeutic approaches, and consequences of enhanced interferon signaling in the kidney.</p><p><strong>Key messages: </strong>Most diagnostic and therapeutic strategies targeting ISGs are still far from clinical implementation. The better understanding of ISG-regulated pathophysiology and the progress of new intervention approaches are expected to facilitate the clinical translation of ISGs-based diagnosis and therapy of kidney diseases.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"390-401"},"PeriodicalIF":3.2,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12165645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between Acute Kidney Injury and Dementia: A Multi-Database Cohort Study.","authors":"Zhixin Guo, Caoxiang She, Yaduan Lin, Shiyu Zhou, Fan Luo, Lisha Cao, Yinfang Sun, Ruixuan Chen, Mingzhen Pang, Xian Shao, Sheng Nie","doi":"10.1159/000545963","DOIUrl":"10.1159/000545963","url":null,"abstract":"<p><strong>Introduction: </strong>With the aging of population, dementia has emerged as a major public health concern, imposing a heavy society burden. However, the relationship between acute kidney injury (AKI) and the risk of dementia remains uncertain.</p><p><strong>Methods: </strong>A total of 1,256,756 participants from the China Renal Data System (CRDS) database and 492,250 individuals from the UK biobank (UKB) dataset were included in the study. The study investigated the associations between AKI and the onset of dementia. The exposure of interest was AKI. The outcome in both the CRDS and UKB cohorts was dementia.</p><p><strong>Results: </strong>The CRDS cohort identified 7,878 patients with new-onset dementia, while the UKB recorded 9,926 dementia cases during follow-up. AKI showed a significant association with the risk of dementia in both the CRDS (adjusted HR: 1.22; 95% confidence interval [CI]: 1.13-1.30, <i>p</i> < 0.001) and UKB cohorts (adjusted HR: 1.64; 95% CI 1.29-1.98, <i>p</i> = 0.005). In the CRDS cohort, patients with more severe AKI (stage 2-3 AKI) (aHR: 1.25; 95% CI 1.09-1.42, <i>p</i> = 0.008) exhibited a higher adjusted HR for dementia compared to those at AKI stage 1 (aHR: 1.21; 95% CI 1.11-1.30, <i>p</i> < 0.001). The association between AKI and dementia remained consistent across different subgroups in both cohorts.</p><p><strong>Conclusion: </strong>Our findings demonstrated that AKI was associated with an elevated risk of all-cause dementia. Consequently, patients with history of AKI episodes necessitate vigilant monitoring for prevention of dementia.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"365-376"},"PeriodicalIF":3.2,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12143866/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144248571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Adherence and the Serum Phosphate, Calcium, and Intact Parathyroid Hormone Control in Peritoneal Dialysis Patients: Effectiveness of Smart PD Care Program.","authors":"Yan Yang, Li Fan, Binbin Lu, Yuanhui Qiu, Zhenhu Chen, Jie Li, Yilin Zeng, Lili Deng, Zhiming Ye, Xueqing Yu","doi":"10.1159/000545964","DOIUrl":"10.1159/000545964","url":null,"abstract":"<p><strong>Introduction: </strong>Patient adherence is important for long-term outcomes of peritoneal dialysis (PD). Artificial intelligence is a good tool to manage patients. However, there are limited data regarding its impact on the patient adherence and the effect of patient adherence on serum phosphate, calcium, and intact parathyroid hormone (iPTH) control in PD patients.</p><p><strong>Methods: </strong>This was a single-center, prospective cohort study including PD patients in Guangdong Provincial People's Hospital. Adult patients (age ≥18 years) who were included in the smart PD care program from September 1, 2020, to April 31, 2023, were enrolled. Patient adherence was assessed using the patient-reported daily PD prescription data and calculated as the total days with PD ultrafiltration reported divided by the total days of follow-up. Good adherence was defined as the reporting rate ≥80%. The primary outcome was serum phosphate, calcium, and iPTH values achieved the treatment targets at 12-month follow-up. Unadjusted and adjusted generalized estimating equations were used to evaluate the association of patient adherence with the serum phosphorus, serum calcium, and iPTH control.</p><p><strong>Results: </strong>A total of 267 patients were included in this study. The mean age of the whole cohort was 43.3 ± 12.8 years, 130 (48.7%) were females, and 52 (19.5%) had diabetes. Patient adherence improved after being included in the smart PD care program and the overall patient adherence during 12-month follow-up was 77.1% ± 26.4%, 93.0% ± 7.4%, and 50.9% ± 25.6% for the entire cohort, patients with good adherence, and those with poor adherence, respectively. Compared to patients with poor adherence, those with good adherence were associated with a better serum calcium (adjusted OR: 3.76; 95% CI: 2.67-5.30; <i>p</i> < 0.001) and iPTH control (adjusted OR: 2.20; 95% CI: 1.56-3.11; <i>p</i> < 0.001) but not for serum phosphorus control (adjusted OR: 1.31; 95% CI: 0.89-1.91; <i>p</i> = 0.17) after being adjusted for potential confounders. Results were similar when assessing the relationship between patient adherence and the longitudinal changes of serum calcium, iPTH, and phosphorus during follow-up.</p><p><strong>Conclusions: </strong>Smart PD care program was effective in improving patient adherence. Good patient adherence was associated with better serum calcium and iPTH control but not for phosphorus control in PD patients. Further studies should be done to evaluate the effect of the smart PD care program on long-term patient outcomes.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"356-364"},"PeriodicalIF":3.2,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Low-Density Lipoprotein Receptor-Related Protein-1 on Acute Kidney Injury and Renal Tubular Epithelial Triglyceride Accumulation.","authors":"Weiteng Wang, Jieyi Luo, Yingwen Chen, Huaban Liang, Zhilian Li, Yuanhan Chen, Jintao He, Xinling Liang","doi":"10.1159/000545851","DOIUrl":"10.1159/000545851","url":null,"abstract":"<p><strong>Introduction: </strong>Various types of acute kidney injury (AKI) are associated with triglyceride (TG) accumulation in renal tubular epithelial cells, but the role and mechanisms of TG accumulation in AKI remain unclear. This study aimed to explore the impact of low-density lipoprotein (LDL) receptor-related protein-1 (LRP1), a protein that mediates TG endocytosis, on ischemia-reperfusion injury (IRI)-induced AKI and TG accumulation in renal tubular epithelial cells.</p><p><strong>Methods: </strong>We established an IRI-induced AKI mouse model and assessed LRP1 expression by Western blot, RT-qPCR, and immunofluorescence. The LRP1 antagonist receptor-associated protein (RAP) was used to evaluate the effect of LRP1 on AKI and renal TG accumulation in the AKI mouse model. We applied a carbonyl cyanide 3-chlorophenylhydrazone (CCCP)-induced hypoxia-reoxygenation model to HK-2 cells in vitro. The effects of very low-density lipoproteins (VLDLs) and LRP1 silencing on TG levels, cell viability, and apoptosis in HK-2 cells were observed.</p><p><strong>Results: </strong>We observed significant TG accumulation in renal tissue during IRI-AKI, accompanied by upregulation of LRP1 in renal tubular epithelial cells. After intervention with the LRP1 antagonist RAP, AKI was significantly alleviated, and TG levels in renal tissue were notably reduced. However, in the in vitro model, although VLDL increased TG levels in HK-2 cells in both normal culture and hypoxia-reoxygenation conditions, it did not alleviate the decrease in cell viability induced by CCCP. In the absence of exogenous VLDL, silencing LRP1 still reduced CCCP-induced TG accumulation and cell apoptosis, although the reduction in TG levels was less pronounced compared to the presence of exogenous VLDL.</p><p><strong>Conclusion: </strong>Our study demonstrated that the increased expression of LRP1 on renal tubular epithelial cells contributes to IRI-induced AKI and TG accumulation. The injury effects of LRP1 on the renal tubules are independent of TG endocytosis. Targeting the inhibition of LRP1 may emerge as a novel therapeutic strategy for AKI.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"320-331"},"PeriodicalIF":3.2,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12112978/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144159797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urinary Myeloid Bodies as a Biomarker for Early Diagnosis and Monitoring of Enzyme Replacement Therapy in Fabry Disease.","authors":"Junlan Yang, Zhiyuan Wei, Haifeng Ni, Qianqian Wu, Siqi Peng, Wen Shi, Xiaoxu Wang, Yan Yang, Jianan Jiang, Jingyuan Cao, Yao Wang, Liyuan Zhang, Aihua Zhang, Xiaoliang Zhang, Bin Wang","doi":"10.1159/000545604","DOIUrl":"10.1159/000545604","url":null,"abstract":"<p><strong>Introduction: </strong>The prevalence of urinary myeloid bodies in Fabry disease patients and their correlation with renal involvement remains unclear.</p><p><strong>Methods: </strong>This single-center, retrospective study included 25 patients with Fabry disease and 27 controls. We analyzed 24-h urine samples for the presence of urinary myeloid bodies and evaluated clinical data, including serum creatinine, estimated glomerular filtration rate (eGFR), 24-h urinary protein levels, α-Gal A, and Lyso-GL-3. Seven Fabry patients underwent analysis of urine samples before and after 1 year of enzyme replacement therapy (ERT).</p><p><strong>Results: </strong>Urinary myeloid bodies were detected in 84% of Fabry patients (21 out of 25), with no significant gender differences. None of the healthy controls or patients with other renal disease patients had urinary myeloid bodies. Among the Fabry patients with myeloid bodies, 48% had no proteinuria, and 52% were in CKD1 stage G1. Furthermore, urinary myeloid bodies were detected in 4 patients under the age of 20, despite the absence of or only minimal proteinuria, and these patients all exhibited a substantial number of myeloid bodies. After 1 year of ERT, significant reductions in both the count (<i>p</i> = 0.043) and area ratio (<i>p</i> = 0.028) of myeloid bodies were observed.</p><p><strong>Conclusion: </strong>Urinary myeloid bodies are specific to Fabry disease and are associated with early renal injury, even in the absence of proteinuria. These findings suggest that urinary myeloid bodies may serve as a noninvasive biomarker for the early diagnosis of Fabry disease and for monitoring the efficacy of ERT.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"332-341"},"PeriodicalIF":3.2,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12119078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144174293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Kidney Injury Molecule-1 and HAVCR1 Polymorphisms as Predictive Biomarkers in Chronic Kidney Disease.","authors":"Nachayada Chaiyagot, Atit Silsirivanit, Ubon Cha'on, Apinya Jusakul, Anchalee Techasen, Kanokwan Nahok, Angkor Chamdam, Sirirat Anutrakulchai, Worachart Lert-Itthiporn","doi":"10.1159/000545831","DOIUrl":"10.1159/000545831","url":null,"abstract":"<p><strong>Introduction: </strong>Kidney injury molecule-1 (KIM-1), encoded by the Hepatitis A Virus Cellular Receptor 1 (<i>HAVCR1</i>) gene, plays a crucial role in kidney injury progression. Although serum and urinary KIM-1 levels are established biomarkers for kidney damage, the relationship between KIM-1 levels, <i>HAVCR1</i> gene polymorphism, and chronic kidney disease (CKD) stages remains unclear. This study aimed to investigate KIM-1 as a potential biomarker for CKD progression in the Thai population and explore its association with genetic polymorphisms in the <i>HAVCR1</i> gene.</p><p><strong>Methods: </strong>A total of 250 patients with CKD were recruited from Khon Kaen, Thailand. Serum and urinary KIM-1 levels were measured using an indirect enzyme-linked immunosorbent assay. Single-nucleotide polymorphism (SNP) genotyping was conducted using the TaqMan assay to assess the associations between KIM-1 levels, SNPs, and CKD progression. Statistical analyses were conducted to assess the correlations between estimated glomerular filtration rate (eGFR), KIM-1 levels, and SNPs.</p><p><strong>Results: </strong>Serum and urinary KIM-1 levels showed a significant negative correlation with eGFR, indicating higher KIM-1 levels in patients with more advanced CKD. However, the rs6555820 SNP in the <i>HAVCR1</i> gene did not show a significant association with KIM-1 levels or eGFR. Interestingly, a significant association between rs6555820 and gender was observed, implying a potential gender-dependent genetic impact.</p><p><strong>Conclusion: </strong>Serum and urinary KIM-1 levels have been found to be associated with CKD stages and eGFR, suggesting their potential as biomarkers for assessing CKD severity. However, no direct associations were observed between the SNP rs6555820 and KIM-1 levels or eGFR. Further research is required to elucidate the genetic mechanisms underlying CKD progression.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"342-355"},"PeriodicalIF":3.2,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12136559/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144225838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.1159/000544850","DOIUrl":"https://doi.org/10.1159/000544850","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000538106.].</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"194"},"PeriodicalIF":3.2,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11984938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Advances in miRNA Biomarkers for Diagnosis and Prognosis of Focal Segmental Glomerulosclerosis.","authors":"Yufei Sun, Shuang Liu, Wan Ding, Chun Zhu, Gengru Jiang, Huilin Li","doi":"10.1159/000545240","DOIUrl":"10.1159/000545240","url":null,"abstract":"<p><strong>Background: </strong>Focal segmental glomerulosclerosis (FSGS) is an increasingly prevalent group of refractory glomerular diseases and a significant aetiology of end-stage renal disease. Podocyte injury and depletion significantly contribute to the pathogenesis and progression of FSGS. MicroRNAs (miRNAs) are noncoding RNAs that regulate the expression of specific genes in relevant cells, thereby playing crucial roles in the pathogenesis of FSGS. Many studies have shown that miRNAs can be secreted from cells into body fluids and that these miRNAs in the circulation are highly stable. The gold standard for FSGS diagnosis is kidney biopsy; however, the clinical heterogeneity of FSGS, along with variations in histology and nonspecific morphological features, can impact its diagnostic accuracy. Thus, the discovery of novel and efficacious biomarkers is crucial in facilitating the diagnosis of FSGS. In addition, the degree of kidney damage in patients with FSGS varies at different stages, necessitating individualized diagnosis and treatment approaches. Considering the side effects of glucocorticoids, determining whether a patient is steroid resistant is vital. Thus, ideal biomarkers should not only be specific and sensitive but also have the ability to accurately reflect the stage or prognosis of the disease to improve the treatment for patients.</p><p><strong>Summary: </strong>To date, numerous studies have shown that both urinary miRNAs and plasma miRNAs are potential biomarkers for FSGS. In addition, the identification of miRNA biomarkers specific for the FSGS disease state may provide new insights into the underlying pathological mechanism of FSGS.</p><p><strong>Key messages: </strong>Here we summarize the currently available miRNA biomarkers that could help us better understand the diagnosis, disease activity, prognosis, and clinical features of FSGS.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"283-291"},"PeriodicalIF":3.2,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12094685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}